101.45 USD
+0.32 (+0.32%)
101.45 USD
0 (0%)
Taking everything into account, EXAS scores 3 out of 10 in our fundamental rating. EXAS was compared to 533 industry peers in the Biotechnology industry. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. EXAS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year EXAS has reported negative net income.
EXAS had a positive operating cash flow in the past year.
In the past 5 years EXAS always reported negative net income.
In multiple years EXAS reported negative operating cash flow during the last 5 years.
1.2 Ratios
EXAS's Return On Assets of -16.72% is fine compared to the rest of the industry. EXAS outperforms 79.17% of its industry peers.
EXAS has a Return On Equity of -39.44%. This is in the better half of the industry: EXAS outperforms 71.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of EXAS (67.37%) is better than 80.30% of its industry peers.
In the last couple of years the Gross Margin of EXAS has declined.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EXAS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EXAS has more shares outstanding
Compared to 1 year ago, EXAS has a worse debt to assets ratio.
2.2 Solvency
EXAS has an Altman-Z score of 2.93. This is not the best score and indicates that EXAS is in the grey zone with still only limited risk for bankruptcy at the moment.
EXAS has a Altman-Z score of 2.93. This is in the better half of the industry: EXAS outperforms 70.17% of its industry peers.
The Debt to FCF ratio of EXAS is 9.47, which is on the high side as it means it would take EXAS, 9.47 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of EXAS (9.47) is better than 90.24% of its industry peers.
A Debt/Equity ratio of 0.93 indicates that EXAS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.93, EXAS is not doing good in the industry: 75.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 2.93 |
ROIC/WACCN/A
WACC8.01%
2.3 Liquidity
A Current Ratio of 2.72 indicates that EXAS has no problem at all paying its short term obligations.
EXAS has a Current ratio of 2.72. This is in the lower half of the industry: EXAS underperforms 66.60% of its industry peers.
A Quick Ratio of 2.44 indicates that EXAS has no problem at all paying its short term obligations.
EXAS has a Quick ratio of 2.44. This is in the lower half of the industry: EXAS underperforms 67.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -354.70%.
EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.47%.
EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
3.2 Future
Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.32% on average per year.
Based on estimates for the next years, EXAS will show a quite strong growth in Revenue. The Revenue will grow by 9.65% on average per year.
EPS Next Y88.42%
EPS Next 2Y44.08%
EPS Next 3Y29.87%
EPS Next 5Y20.32%
Revenue Next Year14.88%
Revenue Next 2Y13.62%
Revenue Next 3Y12.97%
Revenue Next 5Y9.65%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 239.92, EXAS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 86.68% of the companies listed in the same industry.
EXAS's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 239.92 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 89.31% of the companies listed in the same industry.
91.93% of the companies in the same industry are more expensive than EXAS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 77.73 | ||
| EV/EBITDA | 321.27 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 29.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.08%
EPS Next 3Y29.87%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
101.45
+0.32 (+0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.27%
Inst Owner Change1.71%
Ins Owners0.87%
Ins Owner Change1.01%
Market Cap19.21B
Revenue(TTM)3.08B
Net Income(TTM)-986.58M
Analysts85.33
Price Target84.57 (-16.64%)
Short Float %4.24%
Short Ratio3.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)27.37%
PT rev (3m)30.78%
EPS NQ rev (1m)-115.28%
EPS NQ rev (3m)93.75%
EPS NY rev (1m)-1.26%
EPS NY rev (3m)-8.05%
Revenue NQ rev (1m)3.72%
Revenue NQ rev (3m)3.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 239.92 | ||
| P/S | 6.23 | ||
| P/FCF | 77.73 | ||
| P/OCF | 49.65 | ||
| P/B | 7.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 321.27 |
EPS(TTM)-5.32
EYN/A
EPS(NY)0.42
Fwd EY0.42%
FCF(TTM)1.31
FCFY1.29%
OCF(TTM)2.04
OCFY2.01%
SpS16.28
BVpS13.21
TBVpS-4.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% | ||
| FCFM | 8.02% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | 36.88 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 4.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 611.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 2.93 |
F-Score4
WACC8.01%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y88.42%
EPS Next 2Y44.08%
EPS Next 3Y29.87%
EPS Next 5Y20.32%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
Revenue Next Year14.88%
Revenue Next 2Y13.62%
Revenue Next 3Y12.97%
Revenue Next 5Y9.65%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year331.6%
EBIT Next 3Y83.93%
EBIT Next 5Y52.15%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A
EXACT SCIENCES CORP / EXAS FAQ
What is the fundamental rating for EXAS stock?
ChartMill assigns a fundamental rating of 3 / 10 to EXAS.
Can you provide the valuation status for EXACT SCIENCES CORP?
ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.
How profitable is EXACT SCIENCES CORP (EXAS) stock?
EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.